Plasma concentrations of active simvastatin acid are increased by gemfibrozil

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 2, 2000, Pages 122-129

  Backman, Janne T ^a   Kyrklund, Carl ^a   Kivistö, Kari T ^a   Wang, Jun Sheng ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GEMFIBROZIL; ISOENZYME; MIDAZOLAM; SIMVASTATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER METABOLISM; LIVER MICROSOME; MALE; MYOPATHY; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTILIPEMIC AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GEMFIBROZIL; HUMANS; MALE; MICROSOMES, LIVER; SIMVASTATIN;

EID: 0033846824     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.108507     Document Type: Article

References (35)

1. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia
2. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
3. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination
4. Rhabdomyolysis after taking atorvastatin with gemfibrozil
5. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
6. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy
7. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
8. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
9. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
10. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy
11. Gemfibrozil-induced myopathy
12. Rhabdomyolysis seen with simvastatin 160 mg
13. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
14. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin
15. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin
16. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
17. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
18. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
19. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
20. Drug-interaction-induced rhabdomyolysis
21. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s
22. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
23. Microsample determination of lovastatin and its hydroxy acid metabolite in mouse and rat plasma by liquid chromatography/ionspray tandem mass spectrometry
24. Determination of gemfibrozil in plasma by high performance liquid chromatography
25. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation
26. Protein measurement with the Folin phenol reagent
27. Determination of midazolam and its alpha-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography
28. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug
29. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
30. Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients
31. Decreased cyclosporine levels during gemfibrozil treatment of hyperlipidemia after kidney transplantation
32. Potential risk of myopathy by HMG-CoA reductase inhibitors: A comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers
33. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats
34. Pharmacokinetics of the combination of fluvastatin and gemfibrozil
35. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers